💡 Overview & Qucik Summary
Symbiotec Pharmalab Limited IPO Summary: Symbiotec Pharmalab Limited is launching its Initial Public Offering (IPO) of ₹1,757.00 Crore (Fresh Issue: ₹150.00 Cr; OFS: ₹1,607.00 Cr for 1,77,86,442 equity shares) priced in a band of ₹938 to ₹988 per share (Face Value: ₹2/-), open from August 24 to August 27, 2026. The company is a global leader in corticosteroid (38.2% global volume market share) and steroidal-hormone APIs (23.8% share), and is the only company globally present across the top 10 products in both categories (Source: F&S Report). Total income grew 15.4% YoY to ₹872.26 Cr in FY26 with a healthy EBITDA margin of 26.6% (₹231.97 Cr EBITDA). Fresh proceeds are allocated to debt repayment (₹112.50 Cr). Sushil Finance notes that with the OFS exceeding 10x the fresh issue and RoNW softening to 9.48% amid capacity expansion at Ujjain and Mhow, the issue is suitable for risk taking investors.
1. IPO Overview
Symbiotec Pharmalab Limited has announced its Initial Public Offering (IPO) parameters. The issue opens for subscription on August 24, 2026, and closes on August 27, 2026. The price band has been fixed at ₹938 to ₹988 per share with a face value of ₹2/- per share. The total offer comprises 1,77,86,442 equity shares aggregating up to ₹1,757.00 crore.
| Issue Parameter |
Details |
| Price Band |
₹938 to ₹988 Per Share |
| Issue Opens On |
Aug 24, 2026 |
| Issue Closes On |
Aug 27, 2026 |
| Lot Size / Bid Multiples |
15 Shares & in Multiples thereafter |
| Total Issue Size |
₹1,757.00 cr. |
| No. of Shares |
1,77,86,442 |
| Face Value |
₹2/- |
| Listing Stock Exchanges |
BSE & NSE |
| Lead Managers |
JM Financial Ltd., Avendus Capital Pvt. Ltd., Motilal Oswal Investment Advisors Ltd., Nomura Financial Advisory & Securities (India) Pvt. Ltd. |
| Registrar to the Issue |
MUFG Intime India Pvt. Ltd |
2. Key IPO Details & Offer Structure
The total public issue comprises a fresh issuance of equity shares alongside a substantial Offer for Sale (OFS) by the Selling Shareholders. The offer structure and allocation across Qualified Institutional Buyers (QIB), Non-Institutional Investors / High Net-Worth Individuals (HNI), and Retail Individual Investors are summarized below:
Offer Structure
| Issuance |
₹ in Cr. |
| Fresh Issue |
150.00 |
| Offer for Sale (OFS) |
1,607.00 |
| Total |
1,757.00 |
Issue Breakup by Investor Category
| Reservation for |
% of Issue |
₹ in Cr. at upper band |
| QIB |
50% |
878.50 |
| HNI |
35% |
614.95 |
| RETAIL |
15% |
263.55 |
| TOTAL |
100% |
1,757.00 |
3. Company Overview
Symbiotec Pharmalab Limited is a research and development-driven, science-based pharmaceutical and biotechnology company with capabilities spanning three platforms: organic chemistry, biotechnology, and complex injectables.
As of Fiscal 2026, the Company holds a global leadership position in corticosteroid and steroidal-hormone active pharmaceutical ingredients (APIs):
- Global Market Share: Holds a global volume market share of 38.2% in corticosteroids and 23.8% in steroidal-hormone APIs.
- Unrivaled Portfolio Breadth: It is the only Indian and global company present across the top 10 corticosteroid and steroidal-hormone APIs (Source: F&S Report) — a genuinely rare, globally-verified leadership claim.
- Decades of Operating Heritage: With over 30 years of industry experience, the Company has evolved from a lab-scale steroidal-hormone API manufacturer in 1995 into an industrial-scale, backward-integrated platform.
- Global Regulatory Accreditations: Holds stringent approvals from major international regulatory bodies including the US FDA, EU-GMP, and Korea's Ministry of Food and Drug Safety, among other global regulators.
4. Objects of the Issue
The Offer comprises a fresh issue aggregating up to ₹150.00 crore plus a substantial offer for sale aggregating up to ₹1,607.00 crore by the Selling Shareholders (OFS proceeds do not accrue to the Company).
The Fresh Issue Net Proceeds will be utilized as follows:
- Debt Repayment / Prepayment: ₹112.50 crore is earmarked for prepayment/repayment of outstanding borrowings.
- General Corporate Purposes: The balance fresh issue proceeds (capped at 25% of gross proceeds) will be utilized for general corporate purposes.
Notably, the OFS component (₹1,607.00 crore) is more than 10 times the size of the fresh issue — meaning the vast majority of this offer represents existing shareholders monetizing their holdings rather than capital being raised for the Company's own growth or balance-sheet needs.
5. Key Investment Highlights
- Global Leadership in Niche APIs: Global leadership in corticosteroid and steroidal-hormone APIs with leading global volume market shares.
- Deep, Tenured Customer Relationships: Long-standing relationships with a domestic and global customer base of 200+ customers in 40+ countries, with average top-customer relationship tenure exceeding 10 years.
- Fully-Invested, Vertically Integrated Manufacturing Platform: Fully-invested, multi-scale, vertically integrated manufacturing platform with sustainable practices and a clean regulatory track record (US FDA, EU-GMP approved).
- Differentiated Chemistry Capabilities: Differentiated chemistry capabilities enabling up to 400-step synthesis validated under cGMP.
- Domestic Revenue Leadership: Highest revenue among Indian API manufacturers from corticosteroid and steroidal-hormone API sales over the three preceding fiscals.
6. Brief Financial Performance & Metrics
*Not Annualized
| Particulars (₹ in Cr.) |
2026 |
2025 |
2024 |
| Total Income |
723.33 |
755.98 |
872.26 |
| Total Expenditure |
590.99 |
608.85 |
709.90 |
| EBITDA |
177.04 |
206.11 |
231.97 |
| Profit Before Tax (PBT) |
130.98 |
146.98 |
153.36 |
| Profit After Tax (PAT) |
100.06 |
96.79 |
109.90 |
| E.P.S. (Diluted) (₹) |
18.00 |
17.36 |
19.00 |
| RONW (%) |
13.90% |
11.79% |
9.48% |
7. IPO Timeline & Payment Charts
Indicative Time Table
| Tentative Events |
Indicative Dates |
| Finalisation of Basis of Allotment with the Designated Stock Exchange |
28/8/2026 |
| Initiation of refunds / unblocking ASBA Fund |
31/8/2026 |
| Credit of Equity Shares to demat accounts of Allottees |
31/8/2026 |
| Commencement of trading of the Equity Shares on the Stock Exchanges |
1/9/2026 |
Retail Category Price Chart (@ ₹988 Upper Band)
| LOT SIZE (No. of Shares) |
Amount (₹) |
| 15 | 14,820 |
| 30 | 29,640 |
| 45 | 44,460 |
| 60 | 59,280 |
| 75 | 74,100 |
| 90 | 88,920 |
| 105 | 1,03,740 |
| 120 | 1,18,560 |
| 135 | 1,33,380 |
| 150 | 1,48,200 |
| 165 | 1,63,020 |
| 180 | 1,77,840 |
| 195 | 1,92,660 |
HNI Payment Chart
| Category |
No. of Shares |
Minimum Bid Lot Amount (₹) |
| Small HNI |
210 |
2,07,480 |
| Big HNI |
1,020 |
10,07,760 |
8. Our View / Recommendation
Analyst Recommendation: SUITABLE FOR RISK TAKING INVESTORS
Sushil Finance Research Stance & Valuation View
Total income grew steadily from ₹755.98 crore to ₹872.26 crore in FY26 (15.4% YoY), and EBITDA rose from ₹206.11 crore to ₹231.97 crore, with EBITDA margin holding in a healthy 26.6% range — which is solid, consistent execution for a specialty API manufacturer.
The Company's global leadership position (38.2% corticosteroid share, sole presence across the top 10 products globally in two categories) is a genuine, hard-to-replicate moat built over 30 years, reinforced by extensive regulatory approvals that create real barriers to entry.
That said, RoNW has declined every year from 13.90% to 11.79% to 9.48% even as absolute profit grew, reflecting a growing net-worth base outpacing profit growth, likely tied to the Company's recent capacity expansion (two new facilities at Ujjain and Mhow).
The more significant factor for investors to weigh is offer structure: with the OFS more than 10x the size of the fresh issue, this listing is overwhelmingly a monetization event for existing shareholders rather than a capital-raise for growth. It is suitable for risk taking investors.
9. Frequently Asked Questions (FAQs)
Q1. What is the business profile of Symbiotec Pharmalab Limited?
Symbiotec Pharmalab is an R&D-driven, science-based pharma and biotech company specializing in organic chemistry, biotechnology, and complex injectables, holding global leadership in corticosteroid and steroidal-hormone APIs.
Q2. What is the global market share of Symbiotec Pharmalab in corticosteroids?
As of Fiscal 2026, Symbiotec holds a global volume market share of 38.2% in corticosteroids and 23.8% in steroidal-hormone APIs, and is the only global company present across the top 10 APIs in both categories.
Q3. What is the price band and minimum investment for retail investors?
The price band is ₹938 to ₹988 per share. The minimum bid lot is 15 shares, requiring a minimum retail application amount of ₹14,820 at the upper band of ₹988.
Q4. How will the fresh issue proceeds be deployed?
Out of the ₹150 crore fresh issue net proceeds, ₹112.50 crore is earmarked for prepayment/repayment of outstanding borrowings, with the remaining balance allocated for general corporate purposes.
Q5. Why does Sushil Finance classify this IPO as suitable for risk taking investors?
While the company demonstrates strong market leadership and healthy 26.6% EBITDA margins, RoNW has softened from 13.90% to 9.48% due to capacity expansion at Ujjain and Mhow, and the issue is heavily weighted toward OFS (>10x the fresh issue size).
10. Red Herring Prospectus (RHP) Reference
11. Disclaimer
The content provided in this blog is for informational and educational purposes only and should not be construed as investment, legal, or tax advice. While Sushil Finance makes reasonable efforts to ensure accuracy and reliability of the information, we do not guarantee its completeness or timeliness. Readers are advised to consult with their financial advisor before making any investment decisions. Sushil Finance shall not be held responsible for any direct or indirect loss arising from use of this content. Investments in securities are subject to market risks. Read all scheme-related documents carefully before investing.
